A novel synthesis of Mizoribine and related nucleosides from acyclic precursors

Article abstract of DOI:10.1080/15257779508012385

Mizoribine (4-carbamoyl-1-β-D-ribofuranosylimidazolium-5-olate)(13β) and its 4-cyano analogue (20) were synthesized by formation of a malonamide from 2,3-isopropylidene-D-ribosylamine and a malonic acid derivative followed by amination, cyclisation and deprotection steps.

Full text of DOI:10.1080/15257779508012385

This article was downloaded by: [Stanford University Libraries]
On: 06 August 2012, At: 07:30
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered
office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK
Nucleosides and Nucleotides
Publication details, including instructions for authors and
subscription information:
http://www.tandfonline.com/loi/lncn19
A Novel Synthesis of Mizoribine® and
Related Nucleosides from Acyclic
Precursors
David F. Ewing a , Robert W. Humble a , Grahame Mackenzie a &
Gordon Shaw b
a School of Chemistry, University of Hull, Hull, HU6 7RX, UK
b School of Chemistry and Chemical Technology, University of
Bradford, Bradford, BD7 1DP, UK.
Version of record first published: 16 Feb 2007
To cite this article: David F. Ewing, Robert W. Humble, Grahame Mackenzie & Gordon Shaw (1995):
A Novel Synthesis of Mizoribine® and Related Nucleosides from Acyclic Precursors, Nucleosides and
Nucleotides, 14:3-5, 369-372
To link to this article: http://dx.doi.org/10.1080/15257779508012385
PLEASE SCROLL DOWN FOR ARTICLE
Full terms and conditions of use: http://www.tandfonline.com/page/terms-and-conditions
This article may be used for research, teaching, and private study purposes. Any
substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing,
systematic supply, or distribution in any form to anyone is expressly forbidden.
The publisher does not give any warranty express or implied or make any representation
that the contents will be complete or accurate or up to date. The accuracy of any
instructions, formulae, and drug doses should be independently verified with primary
sources. The publisher shall not be liable for any loss, actions, claims, proceedings,
demand, or costs or damages whatsoever or howsoever caused arising directly or
indirectly in connection with or arising out of the use of this material.